文献速递心脑血管急症复苏、休克与脓毒症重症综合管理与镇静镇痛

急性心肌梗死合并心源性休克患者使用血管内微轴流左心室辅助装置与主动脉内球囊反搏的临床结局与费用比较

Clinical Outcomes and Cost Associated With an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump in Patients Presenting With Acute Myocardial Infarction Complicated by Cardiogenic Shock.
PubMed 文献 · JAMA Intern Med · 2022-01-01
一句话结论倾向匹配队列显示,AMI合并CS行PCI患者使用血管内微轴流LVAD较IABP与更高的院内、30天及1年死亡、出血、肾脏替代治疗和费用相关。

该回顾性倾向匹配队列研究利用美国14个州商业保险行政索赔数据,纳入2015年1月1日至2020年4月30日因急性心肌梗死合并心源性休克接受PCI的患者,比较使用血管内微轴流左心室辅助装置(LVAD)与主动脉内球囊反搏(IABP)的临床结局与费用。在817对倾向匹配患者中,LVAD组院内死亡36.2% vs IABP组25.8%(OR 1.63;95%CI 1.32-2.02),30天死亡40.1% vs 28.3%(OR 1.71;95%CI 1.37-2.13),1年死亡58.9% vs 45.0%(HR 1.44;95%CI 1.21-1.71)。30天时LVAD组出血19.1% vs 14.5%(OR 1.35;95%CI 1.04-1.76)、肾脏替代治疗12.2% vs 7.0%(OR 1.88;95%CI 1.30-2.73)、平均费用增加51,680美元(95%CI 31,488-75,178美元);1年时出血29.7% vs 24.3%(HR 1.36;95%CI 1.05-1.75)、肾脏替代治疗18.1% vs 10.9%(HR 1.95;95%CI 1.35-2.83)、平均费用增加46,609美元(95%CI 22,126-75,461美元)持续存在。作者认为,需要更多证据来确定AMI合并CS患者的最佳管理策略。

要点

  • 817对倾向匹配患者中,LVAD组院内死亡36.2% vs IABP组25.8%(OR 1.63;95%CI 1.32-2.02),30天死亡40.1% vs 28.3%(OR 1.71;95%CI 1.37-2.13)。
  • 1年死亡LVAD组58.9% vs IABP组45.0%(HR 1.44;95%CI 1.21-1.71)。
  • 30天出血LVAD组19.1% vs IABP组14.5%(OR 1.35;95%CI 1.04-1.76),肾脏替代治疗12.2% vs 7.0%(OR 1.88;95%CI 1.30-2.73)。
  • 30天平均费用LVAD组较IABP组增加51,680美元(95%CI 31,488-75,178美元),1年增加46,609美元(95%CI 22,126-75,461美元)。
  • 1年出血LVAD组29.7% vs IABP组24.3%(HR 1.36;95%CI 1.05-1.75),肾脏替代治疗18.1% vs 10.9%(HR 1.95;95%CI 1.35-2.83)。

适用人群与场景

  • 因急性心肌梗死合并心源性休克接受经皮冠状动脉介入治疗的患者,数据来自美国14个州商业保险行政索赔,2015年1月1日至2020年4月30日。
  • 全部3077例患者平均(SD)年龄65.2(12.5)岁,986例(32.0%)发生心脏骤停。

研究设计与关键结果

  • 回顾性倾向匹配队列研究,使用美国14个州商业保险行政索赔数据,纳入2015年1月1日至2020年4月30日因AMI合并CS行PCI的患者3077例,比较血管内微轴流LVAD与IABP,倾向匹配后817对。
  • 院内死亡:LVAD组36.2% vs IABP组25.8%(OR 1.63;95%CI 1.32-2.02);30天死亡:40.1% vs 28.3%(OR 1.71;95%CI 1.37-2.13);1年死亡:58.9% vs 45.0%(HR 1.44;95%CI 1.21-1.71)。
  • 30天出血:LVAD组19.1% vs IABP组14.5%(OR 1.35;95%CI 1.04-1.76);30天肾脏替代治疗:12.2% vs 7.0%(OR 1.88;95%CI 1.30-2.73);30天平均费用增加51,680美元(95%CI 31,488-75,178美元)。
  • 1年出血:LVAD组29.7% vs IABP组24.3%(HR 1.36;95%CI 1.05-1.75);1年肾脏替代治疗:18.1% vs 10.9%(HR 1.95;95%CI 1.35-2.83);1年平均费用增加46,609美元(95%CI 22,126-75,461美元)。

证据类型、等级与局限

  • 证据类型:回顾性倾向匹配队列研究,使用行政索赔数据。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在因AMI合并CS行PCI的患者中,与IABP相比,血管内微轴流LVAD的使用与更高的短期和1年死亡、出血、肾脏替代治疗风险及费用相关。
  • 作者认为,迫切需要更多证据来确定AMI合并CS患者的最佳管理策略。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Intravascular microaxial left ventricular assist device (LVAD) compared with intra-aortic balloon pump (IABP) has been associated with increased risk of mortality and bleeding among patients with acute myocardial infarction (AMI) and cardiogenic shock (CS) undergoing percutaneous coronary intervention (PCI). However, evidence on the association of device therapy with a broader array of clinical outcomes, including data on long-term outcomes and cost, is limited.

OBJECTIVE: To examine the association between intravascular LVAD or IABP use and clinical outcomes and cost in patients with AMI complicated by CS.

DESIGN, SETTING, AND PARTICIPANTS: This retrospective propensity-matched cohort study used administrative claims data for commercially insured patients from 14 states across the US. Patients included in the analysis underwent PCI for AMI complicated by CS from January 1, 2015, to April 30, 2020. Data analysis was performed from April to November 2021.

EXPOSURES: Use of either an intravascular LVAD or IABP.

MAIN OUTCOMES AND MEASURES: The primary outcomes were mortality, stroke, severe bleeding, repeat revascularization, kidney replacement therapy (KRT), and total health care costs during the index admission. Clinical outcomes and cost were also assessed at 30 days and 1 year.

RESULTS: Among 3077 patients undergoing PCI for AMI complicated by CS, the mean (SD) age was 65.2 (12.5) years, and 986 (32.0%) had cardiac arrest. Among 817 propensity-matched pairs, intravascular LVAD use was associated with significantly higher in-hospital (36.2% vs 25.8%; odds ratio [OR], 1.63; 95% CI, 1.32-2.02), 30-day (40.1% vs 28.3%; OR, 1.71; 95% CI, 1.37-2.13), and 1-year mortality (58.9% vs 45.0%; hazard ratio [HR], 1.44; 95% CI, 1.21-1.71) compared with IABP. At 30 days, intravascular LVAD use was associated with significantly higher bleeding (19.1% vs 14.5%; OR, 1.35; 95% CI, 1.04-1.76), KRT (12.2% vs 7.0%; OR, 1.88; 95% CI, 1.30-2.73), and mean cost (+$51 680; 95% CI, $31 488-$75 178). At 1 year, the association of intravascular LVAD use with bleeding (29.7% vs 24.3%; HR, 1.36; 95% CI, 1.05-1.75), KRT (18.1% vs 10.9%; HR, 1.95; 95% CI, 1.35-2.83), and mean cost (+$46 609; 95% CI, $22 126-$75 461) persisted.

CONCLUSIONS AND RELEVANCE: In this propensity-matched analysis of patients undergoing PCI for AMI complicated by CS, intravascular LVAD use was associated with increased short-term and 1-year risk of mortality, bleeding, KRT, and cost compared with IABP. There is an urgent need for additional evidence surrounding the optimal management of patients with AMI complicated by CS.

来源:JAMA Intern Med,查看原文。版权归原作者所有。

参考来源

  1. Miller PE, Bromfield SG, Ma Q, et al. Clinical Outcomes and Cost Associated With an Intravascular Microaxial Left Ventricular Assist Device vs Intra-aortic Balloon Pump in Patients Presenting With Acute Myocardial Infarction Complicated by Cardiogenic Shock. JAMA Intern Med. 2022. PMID: 35849410. doi:10.1001/jamainternmed.2022.2735

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。